1. Department of Cardiology, Affiliated Hospital of Academy of Military Medical Sciences,Beijing 100071,China; 2. No. 61 Research Institute of Equipment Development,Academy of Military Sciences, Beijing 100141,China
Abstract：Objective To evaluate the predictive value of cardiac troponin I (hs-cTnI) and N terminal brain natriuretic peptide (NT-proBNP) for cardiac toxicity induced by trastuzumab.Methods Clinical data on 117 patients with breast cancer treated in our hospital with anthracycline chemotherapy and sequential therapy of trastuzumab was collected. At baseline (visit1),before administration of anthracycline (visit2), 3 months into the administration of trastuzumab and paclitaxel(visit3), 6 months into the administration of trastuzumab,hs- cTnI and NT-proBNP levels were detected.The follow-up was 15 months. Echocardiography and questionnaires were used every three months(a total of 6 times).The patients were divided into two groups according to the diagnostic criteria of cardiac toxicity to assess the predictive value of hs-cTnI and NT-proBNP in the cardiac toxicity of trastuzumab.Results There were 16 cases of cardiac toxicity. and the difference in hs-cTnI levels at Visit2 and Visit3 was statistically significant between the cardiac toxicity group and the non cardiac toxicity group (P＜0.05), while levels of NT-proBNP were significantly different between the two groups only 3 months into trastuzumab treatment(P＜0.01). ROC curve analysis of the serum hs-cTnI and NT-proBNP concentrations suggested that the AUC, specificity and sensitivity of hs-cTnI were quite good.Conclusions hs-cTnI can serve as a predictive biomarker of cardiac toxicity s induced by trastuzumab.
Seidman A, Hudis C, Pierri M K,et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. J Clin Oncol,2002,20(5):1215-1221.
[2]
Yeh E T, Bickford C L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management[J]. J Am Coll Cardiol,2009,53(24):2237-2247.
[3]
Slamon D, Eiermann W, Robert N,et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011,365(14):1273-1283.
[4]
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011,365:1273-1283.
[5]
Guarneri V, Lenihan D J, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD anderson cancer center experience[J]. J Clin Oncol,2006, 24(25):4107-4115.
[6]
Roth H J, Leithauser R M, Doppelmayr H,et al. Cardiospecificity of the 3rd generation cardiac troponin T assay during and after a 216 km ultra-endurance marathon run in Death Valley[J]. Clin Res Cardiol,2007,96(6):359-364.
[7]
Kurz K, Voelker R, Zdunek D,et al. Effect of stress-induced reversible ischemia on serum concentrations of ischemiamodified albumin, natriuretic peptides and placental growth factor[J]. Clin Res Cardiol,2007,96(3):152-159.
[8]
Mackey J R, Clemons M, Cté M A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group[J]. Curr Oncol,2008,15:24-35.
[9]
Seidman A, Hudis C, Pierri M K,et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. J Clin Oncol,2002,20(5):1215-1221.
[10]
张瑞生.关注抗肿瘤治疗的心血管毒性[J].中国心血管杂志,2016,21(5):359-362.
[11]
Hilmer S N, Cogger V C, Muller M,et al . The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab[J]. Dispos,2004,32(8):794-799.
[12]
Slamon D J, Leyland-Jones B, Shak S,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl[J]. J Med,2001,344(11):783-792.
[13]
Morris P G,Hudis C A. Anthracyclines and trastuzumab,getting to the heart of the matter: when getting to the heart is the matter[J].Breast Cancer Res Treat,2011,127(2):585-586.
[14]
Ewer M S, Vooletich M T, Durand J B,et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment[J]. J Clin Oncol, 2005,23(31):7820-7826.
Sawaya H, Sebag I A, Plana J C,et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients[J].Am J Cardiol,2011,107(9):1375-1380.
[18]
Pichon M F, Cvitkovic F, Hacene K,et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography[J].In vivo,2005,19(3):567-576.
[19]
Romano S, Fratini S, Ricevuto E,et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients[J]. Br J Cancer,2011,105(11):1663-1668.
[20]
Sandri M T, Salvatici M, Cardinale D,et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction[J].Clin Chem,2013,51(8):14.
[21]
Lipshultz S E, Scully R E, Lipsitz S R,et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial[J].Lancet Oncol,2010,11(10):950-961.
[22]
Cardinale D, Colombo A, Lamantia G,et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy[J].J Am Coll Cardiol,2010,55(3):213-220.
[23]
Cardinale D, Sandri M T, Colombo A,et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy[J].Circulation,2004,109(22):2749-2754.
2017, Vol. 28 
